Stockscreener 앱 받기
9.63
1.93%
-0.19
시간 외 거래:
9.63
전일 마감가:
$9.82
열려 있는:
$9.67
하루 거래량:
111.04K
Relative Volume:
1.06
시가총액:
$138.85M
수익:
$166.88M
순이익/손실:
$-74.18M
주가수익비율:
-1.8994
EPS:
-5.07
순현금흐름:
$1.14M
1주 성능:
-1.13%
1개월 성능:
+6.17%
6개월 성능:
-35.15%
1년 성능:
-43.59%
1일 변동 폭
$9.4001
$9.85
1주일 범위
$9.4001
$9.9698
52주 변동 폭
$7.8701
$18.37
Anika Therapeutics Inc Stock (ANIK) Company Profile
명칭
Anika Therapeutics Inc
전화
(781) 457-9000
주소
32 WIGGINS AVENUE, BEDFORD, MA
ANIK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
9.63 | 141.59M | 166.88M | -74.18M | 1.14M | -5.07 |
|
ZTS
Zoetis Inc
|
124.46 | 63.97B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.56 | 42.40B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.32 | 41.77B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.46 | 23.54B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
437.33 | 18.89B | 3.08B | 1.24B | 1.07B | 25.61 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-17 | 개시 | B. Riley Securities | Buy |
| 2024-11-01 | 재확인 | Barrington Research | Outperform |
| 2023-08-14 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2023-03-07 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2022-11-09 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2022-10-14 | 재개 | Stephens | Equal-Weight |
| 2022-03-09 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2022-03-09 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2021-11-16 | 개시 | Stephens | Overweight |
| 2021-07-16 | 개시 | UBS | Neutral |
| 2020-12-16 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2020-05-08 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2020-01-21 | 업그레이드 | Sidoti | Neutral → Buy |
| 2020-01-10 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2019-11-05 | 개시 | BWS Financial | Sell |
| 2019-09-24 | 재확인 | Barrington Research | Outperform |
| 2019-09-23 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2019-07-25 | 업그레이드 | First Analysis Sec | Neutral → Strong Buy |
| 2019-02-22 | 다운그레이드 | First Analysis Sec | Outperform → Neutral |
| 2019-02-22 | 다운그레이드 | Sidoti | Buy → Neutral |
| 2018-07-27 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2018-06-20 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2018-06-20 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2018-05-04 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2018-02-23 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2018-01-24 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
| 2017-10-27 | 재확인 | Barrington Research | Outperform |
| 2016-05-09 | 업그레이드 | Singular Research | BUY - Long-Term → Buy |
| 2016-04-27 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2016-02-26 | 재확인 | Barrington Research | Outperform |
모두보기
Anika Therapeutics Inc 주식(ANIK)의 최신 뉴스
Anika Therapeutics Inc (ANIK) Q3 2025 Earnings Report Preview: W - GuruFocus
Anika Therapeutics Inc (ANIK) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Using AI based signals to follow Anika Therapeutics Inc.July 2025 Fed Impact & Fast Entry High Yield Stock Tips - newser.com
Why Anika Therapeutics Inc. stock could rally in 2025Trade Exit Summary & Reliable Price Breakout Alerts - newser.com
Strategies to average down on Anika Therapeutics Inc.2025 Trading Volume Trends & AI Driven Stock Reports - newser.com
Will Anika Therapeutics Inc. stock reach all time highs in 20252025 Big Picture & Daily Stock Trend Watchlist - newser.com
What dividend safety rating applies to Anika Therapeutics Inc. (AKP) stockGap Up & Low Risk Entry Point Guides - newser.com
Orthopedic Regenerative Medicine with Detailed Study Analysis 2025-2032 | Anika Therapeutics, Inc and Arthrex - openPR.com
Is Anika Therapeutics Inc. stock undervalued vs historical averagesWeekly Investment Report & Low Drawdown Momentum Ideas - newser.com
What is the fair value estimate for Anika Therapeutics Inc. (AKP) stock in 2025Quarterly Portfolio Review & Entry Point Confirmation Signals - newser.com
Key metrics from Anika Therapeutics Inc.’s quarterly dataPortfolio Performance Report & AI Forecast Swing Trade Picks - newser.com
Anika Therapeutics Inc expected to post a loss of 27 cents a shareEarnings Preview - TradingView
Does Anika Therapeutics Inc. show high probability of rebound2025 Performance Recap & Comprehensive Market Scan Insights - newser.com
Why Anika Therapeutics Inc. stock could outperform in 2025July 2025 Rallies & AI Driven Stock Reports - newser.com
Detecting support and resistance levels for Anika Therapeutics Inc.Market Performance Recap & Advanced Technical Signal Analysis - newser.com
Is Anika Therapeutics Inc. stock positioned for long term growthJuly 2025 Momentum & Daily Profit Focused Screening - newser.com
Anika Therapeutics Inc. (ANIK) Stock forecasts - Yahoo! Finance UK
Published on: 2025-11-02 07:06:18 - newser.com
Anika Therapeutics Inc. (ANIK) stock forecast and price target - Yahoo! Finance UK
Anika Therapeutics, Inc. (ANIK) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Anika Therapeutics, Inc. (ANIK) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Is Anika Therapeutics Inc. stock supported by strong cash flowsEntry Point & Low Drawdown Trading Strategies - newser.com
Anika Therapeutics (NASDAQ:ANIK) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
Anika Therapeutics Inc (ANIK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Anika Therapeutics Inc 주식 (ANIK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nunes Anne | SVP, Chief Operations Officer |
Mar 17 '25 |
Option Exercise |
0.00 |
3,637 |
0 |
21,722 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 17 '25 |
Option Exercise |
0.00 |
6,448 |
0 |
49,847 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 17 '25 |
Option Exercise |
0.00 |
25,132 |
0 |
209,472 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '25 |
Option Exercise |
0.00 |
2,561 |
0 |
18,837 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '25 |
Option Exercise |
0.00 |
7,663 |
0 |
45,649 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 11 '25 |
Option Exercise |
0.00 |
30,060 |
0 |
197,015 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
3,296 |
0 |
17,235 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 10 '25 |
Option Exercise |
0.00 |
5,465 |
0 |
39,590 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 10 '25 |
Option Exercise |
0.00 |
20,002 |
0 |
172,826 |
3.60%
0.45%
자본화:
|
볼륨(24시간):